Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Other Non-Current Assets (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Other Non-Current Assets for 6 consecutive years, with $29.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $29.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.0 million, a N/A change, with the full-year FY2025 number at $29.0 million, changed N/A from a year prior.
  • Other Non-Current Assets was $29.0 million for Q4 2025 at Lexicon Pharmaceuticals, roughly flat from $29.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $29.0 million in Q3 2025 to a low of $368000.0 in Q1 2025.
  • A 3-year average of $6.9 million and a median of $828000.0 in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: crashed 87.1% in 2024, then skyrocketed 3402.42% in 2025.
  • Lexicon Pharmaceuticals' Other Non-Current Assets stood at $828000.0 in 2023, then changed by 0.0% to $828000.0 in 2024, then surged by 3402.42% to $29.0 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Other Non-Current Assets are $29.0 million (Q4 2025), $29.0 million (Q3 2025), and $368000.0 (Q2 2025).